Therefore, more new insights into the mechanisms of regulating MYCN expression or protein stability will not only help to drive development of new therapeutic strategies to combat MYCN-amplified NB, but also help to understand the underlying mechanisms for drug resistance during the treatment of NB patients which will benefit the development of strategies for personalized medicine. This evidence concerns the gene MYCN and neuroblastoma.